mmunotherapy targeting programmed cell death 1 (PD-1) and PD-ligand 1 (PD-L1) has shown promise in treating human cancers. 

A new study evaluated canine PD-L1 expression in various cancer types, using a new anti-PD-L1 mAb, 6C11-3A11 in 29 dogs with pulmonary metastatic oral malignant melanoma (OMM). 

Survival was significantly longer in the treatment group (median 143 days) when compared to a control group ( median 54 days). One dog (7.7%) experienced a complete response. 

Treatment-related adverse events were observed in 15 dogs (51.7%).  

Read more by clicking on the link below:

PD-L1 immunohistochemistry for canine cancers and clinical benefit of anti-PD-L1 antibody in dogs with pulmonary metastatic oral malignant melanoma